Iovance Biotherapeutics: The High-Risk Cancer Stock I Think Could Change a Portfolio by 2036 [Yahoo! Finance]
Iovance Biotherapeutics (IOVA) had its price target raised by UBS Group AG from $2.00 to $4.00. They now have a "neutral" rating on the stock.
Iovance Biotherapeutics (IOVA) was upgraded by Citizens Jmp from "market perform" to "market outperform". They now have a $5.00 price target on the stock.
Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success [Yahoo! Finance]
Is Iovance Biotherapeutics (IOVA) Pricing Reflect Recent Cell Therapy Progress Accurately [Yahoo! Finance]